NanoViricides Remdesivir-Encapsulated COVID Therapy Shows Encouraging Preclinical Safety Profile
- NanoViricides Inc (Get Free Alerts for NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-coronavirus cure.
- The Company is currently pursuing two COVID-19 drug candidates.
- NV-CoV-2 is a nanoviricide drug candidate that does not encapsulate remdesivir.
- NV-CoV-2-R is another candidate made up of NV-CoV-2 with remdesivir encapsulated in it. Remdesivir was developed by Gilead Sciences Inc .
- The animal study showed that almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, compared to the standard remdesivir formulation in Sulfobutylether-β-cyclodextrin sodium salt (SBECD), during the first day of dosing.
- Additionally, remdesivir accumulation was observed on repeated dosing of NV-CoV-2-R.
- After the fifth dose and following the standard remdesivir dosing pattern, the circulating level of remdesivir in plasma was 75% greater in the NV-Cov-2-R group than in the remdesivir group.
- The increased intact circulating level did not increase toxicity.
- These data demonstrate that the pan-coronavirus nanopviricide drug candidate NV-CoV-2-R minimizes the loss of remdesivir to bodily metabolism.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.